Physician profile
Albert C Yan
NPI 1780690875
$33,656.91
in general payments reported to CMS, 2019-2025
9 companies · $2,194 in 2025
The $2,194 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2021: $4,291 · 2022: $4,105 · 2023: $12K · 2024: $61.09 · 2025: $2,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,010 · Travel and Lodging: $3,229 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Food and Beverage: $479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,010.00 |
| Travel and Lodging | $3,229.03 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Food and Beverage | $479.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $9,706.40 | 2021-2023 | |
| Pfizer INC. | $6,091.46 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $5,328.19 | 2023 | Hemangeol |
| Regeneron Healthcare Solutions, INC. | $2,800.93 | 2019 | |
| Boehringer Ingelheim International Gmbh | $2,750.00 | 2022 | |
| Janssen Scientific Affairs, LLC | $2,193.84 | 2025 | |
| Arcutis Biotherapeutics, INC. | $1,875.00 | 2023 | |
| Aclaris Therapeutics, INC. | $1,650.00 | 2019 | |
| Verrica Pharmaceuticals INC. | $1,261.09 | 2023-2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Yan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.